Holen Sie sich die Stockscreener-App
1.27
0.78%
-0.01
Schlusskurs vom Vortag:
$1.28
Offen:
$1.28
24-Stunden-Volumen:
130.16K
Relative Volume:
0.31
Marktkapitalisierung:
$76.08M
Einnahmen:
$8.38M
Nettoeinkommen (Verlust:
$-27.19M
KGV:
-1.1651
EPS:
-1.09
Netto-Cashflow:
$-13.59M
1W Leistung:
+4.10%
1M Leistung:
+14.41%
6M Leistung:
+27.96%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.24
$1.28
1-Wochen-Bereich:
$1.22
$1.35
52-Wochen-Spanne:
$0.65
$1.75
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Vergleichen Sie IRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.27 | 76.68M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
What MACD and RSI say about Opus Genetics Inc.Weekly Risk Report & Weekly Top Gainers Trade List - Newser
Can Opus Genetics Inc. expand its profit marginsJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - خودرو بانک
Does Opus Genetics Inc. offer margin of safetyJuly 2025 Sector Moves & Capital Efficiency Focused Strategies - خودرو بانک
Statistical indicators supporting Opus Genetics Inc.’s strength2025 Breakouts & Breakdowns & Low Risk High Win Rate Picks - Newser
Opus Genetics Inc. stock trendline breakdown2025 Dividend Review & Verified Entry Point Signals - Newser
Opus Genetics Inc. stock prediction for this weekPortfolio Risk Summary & Real-Time Chart Pattern Alerts - Newser
How high can Opus Genetics Inc. stock goWeekly Gains Summary & Consistent Profit Focused Trading Strategies - Newser
Regression analysis insights on Opus Genetics Inc. performanceMarket Performance Report & AI Forecast for Swing Trade Picks - Newser
Published on: 2025-09-05 06:16:51 - Newser
Smart tools for monitoring Opus Genetics Inc.’s price actionQuarterly Trade Summary & Long-Term Capital Growth Strategies - Newser
Published on: 2025-09-05 05:31:47 - Newser
Opus Genetics begins phase 3 trial for night vision drug after surgery - Investing.com Nigeria
Is Opus Genetics Inc. still a buy after recent gains2025 Trading Volume Trends & Low Volatility Stock Recommendations - خودرو بانک
Park Ha Biological Technology Co., Ltd. shares fall 2.91% after-hours as Opus Genetics doses first patient in pivotal LYNX-3 trial. - AInvest
Using data tools to time your Opus Genetics Inc. exit2025 Analyst Calls & Daily Technical Forecast Reports - Newser
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 - GlobeNewswire
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - Stock Titan
Is Opus Genetics Inc. benefiting from innovation trendsMarket Growth Summary & Safe Capital Growth Tips - خودرو بانک
What does recent volatility data suggest for Opus Genetics Inc.2025 Top Gainers & Daily Volume Surge Signals - Newser
Opus Genetics Inc. stock chart pattern explained2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
Park Ha Biological Technology Co., Ltd. shares rise 1.66% after-hours following Opus Genetics' participation in the H.C. Wainwright 27th Annual Global Investment Conference. - AInvest
Using Bollinger Bands to evaluate Opus Genetics Inc.2025 EndofYear Setup & Verified Momentum Stock Alerts - Newser
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Gene Therapy Leader Opus Genetics to Showcase IRD Pipeline at H.C. Wainwright Global Conference - Stock Titan
Opus Genetics Inc. stock volume spike explainedAnalyst Upgrade & Weekly High Conviction Ideas - Newser
Analyzing recovery setups for Opus Genetics Inc. investorsEarnings Risk Report & Reliable Volume Spike Alerts - Newser
Visualizing Opus Genetics Inc. stock with heatmapsMarket Weekly Review & Weekly High Conviction Ideas - Newser
Trend Review: Is Opus Genetics Inc. stock influenced by commodity pricesTrade Volume Report & Free Technical Pattern Based Buy Signals - خودرو بانک
Will Opus Genetics Inc. continue its uptrendEarnings Growth Report & Safe Capital Growth Tips - Newser
Ranking Opus Genetics Inc. among high performing stocks via toolsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - Newser
Is Opus Genetics Inc. impacted by rising ratesJuly 2025 Short Interest & Weekly High Return Stock Opportunities - خودرو بانک
Harvard Bioscience shares fall 3.03% intraday after Opus Genetics appoints new CFO. - AInvest
Opus Genetics shares rise 6.64% intraday after appointing Rob Gagnon as Chief Financial Officer. - AInvest
Opus Genetics' Strategic CFO Appointment and Its Implications for Biotech Capital Efficiency and Growth - AInvest
Opus Genetics Names Rob Gagnon as New CFO - AInvest
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer - GlobeNewswire
Biotech Veteran Who Raised $2B in Capital Joins Opus Genetics as CFO Ahead of Key Clinical Milestones - Stock Titan
How sentiment analysis helps forecast Opus Genetics Inc.July 2025 Decliners & Weekly Market Pulse Updates - Newser
Bull Bear: Is Opus Genetics Inc. stock heavily shorted2025 Investor Takeaways & Accurate Trade Setup Notifications - خودرو بانک
Comparing Opus Genetics Inc. in custom built stock radarsPortfolio Growth Summary & Daily Growth Stock Tips - Newser
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):